title: Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience.
authors.affiliation: Neuro-Oncology Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. gaviani.p@istituto-besta.it
authors.forename: P
authors.initials: P
authors.lastname: Gaviani
authors.forename: G
authors.initials: G
authors.lastname: Simonetti
authors.forename: A
authors.initials: A
authors.lastname: Salmaggi
authors.forename: E
authors.initials: E
authors.lastname: Lamperti
authors.forename: A
authors.initials: A
authors.lastname: Silvani
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D011379:Prognosis; D011446:Prospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; D009943:Organophosphorus Compounds; C054368:fotemustine